Skip to main content
SpringerLink
Log in
Book cover

Influenza Pathogenesis and Control - Volume II pp 151–180Cite as

Inactivated and Adjuvanted Influenza Vaccines

  • Chapter
  • First Online:

Part of the book series: Current Topics in Microbiology and Immunology ((CT MICROBIOLOGY,volume 386))

Abstract

Inactivated influenza vaccines are produced every year to fight against the seasonal epidemics of influenza. Despite the nonoptimal coverage, even in subjects at risk like the elderly, pregnant women, etc., these vaccines significantly reduce the burden of mortality and morbidity linked to the influenza infection. Importantly, these vaccines have also contributed to reduce the impact of the last pandemics. Nevertheless, the performance of these vaccines can be improved mainly in those age groups, like children and the elderly, in which their efficacy is suboptimal. The use of adjuvants has proven effective to this scope. Oil-in-water adjuvants like MF59 and AS03 have been licensed and widely used, and shown efficacious in preventing influenza infection in the last pandemic. MF59-adjuvanted inactivated vaccine was more efficacious than non-adjuvanted vaccine in preventing influenza infection in young children and in reducing hospitalization due to the influenza infection in the elderly. Other adjuvants are now at different stages of development and some are being tested in clinical trials. The perspective remains to improve the way inactivated vaccines are prepared and to accelerate their availability, mainly in the case of influenza pandemics, and to enhance their efficacy/effectiveness for a more successful impact at the public health level.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD   169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  • Alberini I, Del Tordello E, Fasolo A, Temperton N, Galli G, Gentile C, Montomoli E, Hilbert AK, Banzhoff A, Giuseppe Del Giudice G, Donnelly J, Rappuoli R, Capecchi B (2009) Pseudoparticle neutralization is a reliable assay to measure immunity and cross-reactivity to H5N1 influenza viruses. Vaccine 27:5998–6003

    CAS  PubMed  Google Scholar 

  • Ansaldi F, Bacilieri S, Durando P, Sticchi L, Valle L, Montomoli E, Icardi G, Gasparini R, Crovari P (2008) Cross-protection by MF59-adjuvanted influenza vaccine: neutralizing and hemagglutination-inhibiting antibody activity against A(H3N2) drifted influenza viruses. Vaccine 26:1525–1529

    CAS  PubMed  Google Scholar 

  • Ansaldi F, Zancolli F, Durando P, Montomoli E, Sticchi L, Giuseppe Del Giudice G, Icardi G (2010) Antibody response against heterogeneous circulating influenza virus strains elicited by MF59-and non-adjuvanted vaccines during seasons with good or partical matching between vaccine strain and clinical isolates. Vaccine 28:4123–4129

    CAS  PubMed  Google Scholar 

  • Baldo V, Baldovin T, Floreani A, Minuzzo M, Trivello R (2006) Response to influenza vaccine in people with non-protective HI antibody titers. Eur J Epidemiol 21:843–845

    CAS  PubMed  Google Scholar 

  • Baldo V, Baldovin T, Pellegrini M, Angiolelli G, Majori S, Floreani A, Busana MC, Bertoncello C, Trivello R (2010) Immunogenicity of three different influenza vaccines against homologous and heterologous strains in nursing home elderly residents. Clin Dev Immunol 2010:517198. doi: 10.1155/2010/517198. Epub 2010 Mar 29

  • Banzhoff A, Nacci P, Podda A (2003) A new MF59-adjuvanted influenza vaccine enhances the immune response in the elderly with chronic diseases: Results from an immunogenicity meta-analysis. Gerontology 49:177–184

    CAS  PubMed  Google Scholar 

  • Banzhoff A, Gasparini R, Laghi-Pasini F, Staniscia T, Durando P, Montomoli E, Capecchi PL, Di Giovanni P, Sticchi L, Gentile C, Hilbert A, Brauer V, Tilman S, Podda A (2009) MF59-adjuvanted H5N1 vaccine induces immunologic memory and heterotypic antibody responses in non-elderly and elderly adults. PLoS ONE 4(2):e4384

    PubMed Central  PubMed  Google Scholar 

  • Banzhoff A, Haertel S, Praus M (2011) Passive surveillance of adverse events of an MF59-adjuvanted H1N1v vaccine during the pandemic mass vaccinations. Hum Vaccin 7:539–548

    PubMed  Google Scholar 

  • Barrett PN, Berezuk G, Fritsch S, Aichinger G, Hart MK, El-Amin W, Kistner O, Ehrlich HJ (2011) Efficacy, safety, and immunogenicity of a Vero-cell-culture-derived trivalent influenza vaccine: a multicentre, double-blind, randomised, placebo-controlled trial. Lancet 377:751–759

    CAS  PubMed  Google Scholar 

  • Beebe GW, Simon AH, Vivona S (1972) Long-term mortality follow-up of Army recruits who received adjuvant influenza virus vaccine in 1951-1953. Am J Epidemiol 95:337–346

    CAS  PubMed  Google Scholar 

  • Behzad H, Huckriede AL, Haynes L, Gentleman B, Coyle K, Wilschut JC, Kollmann TR, Reed SG, McElhaney JE (2012) GLA-SE, a synthetic toll-like receptor 4 agonist, enhances T-cell responses to influenza vaccine in older adults. J Infect Dis 205:466–473

    CAS  PubMed Central  PubMed  Google Scholar 

  • Belshe RB (2010) The need for quadrivalent vaccine against seasonal influenza. Vaccine 28(Suppl 4):D45–D53

    PubMed  Google Scholar 

  • Belshe RB, Newman FK, Cannon J, Duane C, Treanor J, Van Hoecke C, Howe BJ, Dubin G (2004) Serum antibody responses after intradermal vaccination against influenza. N Engl J Med 351:2286–2294

    CAS  PubMed  Google Scholar 

  • Belshe RB, Newman FK, Wilkins K, Graham IL, Babusis E, Ewell M, Frey SE (2007) Comparative immunogenicity of trivalent influenza vaccine administered by intradermal or intramuscular route in healthy adults. Vaccine 25:6755–6763

    CAS  PubMed Central  PubMed  Google Scholar 

  • Bentebibel SE, Lopez S, Obermoser G, Schmitt N, Mueller C, Harrod C, Flano E, Mejias A, Albrecht RA, Blankenship D, Xu H, Pascual V, Banchereau J, Garcia-Sastre A, Palucka AK, Ramilo O, Ueno H (2013) Induction of ICOS + CXCR3 + CXCR5 + TH cells correlates with antibody responses to influenza vaccination. Sci Transl Med 5:176ra32

    Google Scholar 

  • Ben-Yehuda A, Joseph A, Zeira E, Even-Chen S, Louria-Hayon I, Babai I, Zakay-Rones Z, Greenbaum E, Barenholz Y, Kedar E (2003) Immunogenicity and safety of a novel liposomal influenza subunit vaccine (INFLUSOME-VAC) in young adults. J Med Virol 69:560–567

    PubMed  Google Scholar 

  • Beran J, Vesikari T, Wertzova V, Karvonen A, Honegr K, Lindblad N, Van Belle P, Peeters M, Innis BL, Devaster JM (2009) Efficacy of inactivated split-virus influenza vaccine against culture-confirmed influenza in healthy adults: a prospective randomized, placebo-controlled trial. J Infect Dis 200:1861–1869

    CAS  PubMed  Google Scholar 

  • Beran J, Peeters M, Dewé W, Raupachova J, Hobzova L, Devaster JM (2013) Immunogenicity and safety of quadrivalent versus trivalent inactivated vaccine: a randomized, controlled trial in adults. BMC Infect Dis 13:224

    CAS  PubMed Central  PubMed  Google Scholar 

  • Bernstein DI, Edwards KM, Dekker CL, Belshe R, Talbot HK, Graham IL, Noah DL, He F, Hill H (2008) Effects of adjuvants on the safety and immunogenicity of an avian influenza H5N1 vaccine in adults. J Infect Dis 197:667–675

    CAS  PubMed  Google Scholar 

  • Beutner KR, Chow T, Rubi E, Strussenberg J, Clement J, Ogra PL (1979) Evaluation of a neuraminidase-specific influenza A virus vaccine in children: antibody responses and effects on two successive outbreaks of natural infection. J Infect Dis 140:844–850

    CAS  PubMed  Google Scholar 

  • Black S, Della Cioppa G, Malfroot A, Nacci P, Nicolay U, Pellegrini M, Sokal E, Vertruyen A (2010) Safety of MF59-adjuvanted versus non-adjuvanted influenza vaccines in children and adolescents: an integrated analysis. Vaccine 28:7331–7336

    CAS  PubMed  Google Scholar 

  • Black S, Nicolay U, Vesikari T, Knuf M, Giuseppe Del Giudice G, Della Cioppa G, Tsai T, Clemens R, Rappuoli R (2011) Hemagglutination inhibition antibody titers as a correlate of protection for inactivated influenza vaccines in children. Pediatr Infect Dis J 30:1081–1085

    PubMed  Google Scholar 

  • Calabro S, Tortoli M, Baudner BC, Pacitto A, Cortese M, O’Hagan DT, De Gregorio E, Seubert A, Wack A (2011) Vaccine adjuvants alum and MF59 induce rapid recruitment of neutrophils and monocytes that participate in antigen transport to draining lymph nodes. Vaccine 29:1812–1823

    CAS  PubMed  Google Scholar 

  • Calabro S, Tritto E, Pezzotti A, Taccone M, Muzzi A, Bertholet S, De Gregorio E, O’Hagan DT, Baudner B, Seubert A (2013) The adjuvant effect of MF59 is due to the oil-in-water emulsion formulation, none of the individual components induce a comparable adjuvant effect. Vaccine 31:3363–3369

    CAS  PubMed  Google Scholar 

  • Camilloni B, Neri M, Lepri E, Iorio AM (2009) Cross-reactive antibodies in middle-aged and elderly volunteers after MF59-adjuvanted subunit trivalent influenza vaccine against B viruses of the B/Victoria or B/Yamagata lineages. Vaccine 27:4099–4103

    CAS  PubMed  Google Scholar 

  • Caproni E, Tritto E, Cortese M, Muzzi A, Mosca F, Monaci E, Baudner B, Seubert A, De Gregorio E (2012) MF59 and Pam3CSK4 boost adaptive responses to influenza subunit vaccine through an IFN type I-independent mechanism of action. J Immunol 188:3088–3098

    CAS  PubMed  Google Scholar 

  • Carrat F, Flahault A (2007) Influenza vaccine: the challenge of antigenic drift. Vaccine 25:6852–6862

    CAS  PubMed  Google Scholar 

  • Centers for Disease Control (2010). Updated CDC estimates of 2009 H1N1 influenza cass, hospitalizations and deaths in the United States, April 2009–April 2010

    Google Scholar 

  • Centers for Disease control (2013) Flu vaccination coverage. http://www.cdc.gov/flu/fluvaxview/coverage-1213estimates.htm. Accessed 23 Dec 2013

  • Chen WH, Cross AS, Edelman R, Sztein M, Blackwelder WC, Pasetti MF (2011) Antibody and Th1-type cell-mediated immune responses in elderly and young adults immunized with standard or a high dose influenza vaccine. Vaccine 29:2865–2873

    CAS  PubMed Central  PubMed  Google Scholar 

  • Christensen D, Korsholm KS, Andersen P, Agger EM (2011) Cationic liposomes as vaccine adjuvants. Expert Rev Vaccines 10:513–521

    CAS  PubMed  Google Scholar 

  • Clements ML, Betts RF, Tierney EL, Murphy BR (1986) Serum and nasal wash antibodies associated with resistance to experimental challenge with influenza A wild-type virus. J Clin Microbiol 24:157–160

    CAS  PubMed Central  PubMed  Google Scholar 

  • Co MDT, Orphin L, Cruz J, Pazoles P, Green KM, Potts J, Leporati AM, Babon JAB, Evans JE, Ennis FA, Terajima M (2009) In vitro evidence that commercial influenza vaccines are not similar in their ability to activate human T cell responses. Vaccine 27:319–327

    PubMed Central  PubMed  Google Scholar 

  • Committee on Infectious Diseases (2013) Recommendations for prevention and control of influenza in children, 2013-2014. Pediatrics 132:e1089–e1104

    Google Scholar 

  • Cooper CL, Davis HL, Morris ML, Efler SM, Krieg AM, Li Y, Laframboise C, Al Adhami MJ, Khaliq Y, Seguin I, Cameron DW (2004) Safety and immunogenicity of CPG 7909 injection as an adjuvant to Fluarix influenza vaccine. Vaccine 22:3136–3143

    CAS  PubMed  Google Scholar 

  • Corti D, Lanzavecchia A (2013) Broadly neutralizing antiviral antibodies. Annu Rev Immunol 31:705–742

    CAS  PubMed  Google Scholar 

  • Coudeville L, Bailleux F, Riche B, Megas F, Andre P, Ecochard R (2010) Relationship between haemagglutinin-inhibiting antibody titres and clinical protection against influenza: development and application of a Bayesian random effects model. BMC Med Res Methodol 10:18

    PubMed Central  PubMed  Google Scholar 

  • Crowe JE Jr (2013) Universal flu vaccines: primum non nocere. Sci Transl Med 5:200fs34

    Google Scholar 

  • Dauvilliers Y, Arnulf I, Lecendreux M, Monaca Charley C, Franco P, Drouot X, d’Ortho MP, Launois S, Lignot S, Bourgin P, Nogues B, Rey M, Bayard S, Scholz S, Lavault S, Tubert-Bitter P, Saussier C, Pariente A, Narcoflu-VF study group (2013) Increased risk of narcolepsy in children and adults after pandemic H1N1 vaccination in France. Brain 136:2486–2496

    PubMed  Google Scholar 

  • Davenport FM (1968) Antigenic enhancement of ether-extracted influenza virus vaccines by AlPO4. Proc Soc Exp Biol Med 127:587–590

    CAS  PubMed  Google Scholar 

  • Davenport FM, Hennessy AV, Bell JA (1962) Immunologic advantages of emulsified influenza virus vaccines. Mil Med 127:95–100

    CAS  PubMed  Google Scholar 

  • Davenport DM, Hennessy AV, Askin FB (1968) Lack of adjuvant effect of AlPO4 on purified influenza virus hemagglutining in man. J Immunol 100:1139–1140

    CAS  PubMed  Google Scholar 

  • Davis DJ, Philip RN, Bell JA, Voegel JE, Jensen DV (1961) Epidemiological studies on influenza in familiar and general population groups 1951-1956. III. Laboratory observations. Am J Hyg 73:138–147

    CAS  Google Scholar 

  • De la Herrán-Arita AK, Kornum BR, Mahlios J, Jiang W, Lin L, Hou T, Macaubas C, Einen M, Plazzi G, Crowe C, Newell EW, Davis MM, Mellins ED, Mignot E (2013) CD4+ T Cell autoimmunity to hypocretin/orexin and cross-reactivity to a 2009 H1N1 influenza A epitope in narcolepsy. Sci Transl Med 5:216ra176

    Google Scholar 

  • Giuseppe Del Giudice G, Hilbert AK, Bugarini R, Minutello A, Popova O, Toneatto D, Schoendorf I, Borkowski A, Rappuoli R, Podda A (2006) An MF59-adjuvanted inactivated influenza vaccine containing A/Panama/1999 (H3N2) induced broader serological protection against heterovariant influenza virus strain A/Fujian/2002 than a subunit and a split influenza vaccine. Vaccine 24:3063–3065

    PubMed  Google Scholar 

  • Giuseppe Del Giudice G, Fragapane E, Della Cioppa G, Rappuoli R (2013) Aflunov®: a vaccine tailored for pre-pandemic and pandemic approaches against influenza. Expert Opin Biol Ther 13:121–135

    PubMed  Google Scholar 

  • Della Cioppa G, Vesikari T, Sokal E, Lindert K, Nicolay U (2011) Trivalent and quadrivalent MF59®-adjuvanted influenza vaccine in young children: a dose-and schedule-finding study. Vaccine 29:8696–8704

    PubMed  Google Scholar 

  • Dolin R (2013) The quadrivalent approach to influenza vaccination. J Infect Dis 208:539–540

    PubMed  Google Scholar 

  • Domachowske JB, Pankow-Culot H, Bautista M, Geng Y, Claeys C, Peeters M, Innis BL, Jain V (2013) A randomized trial of candidate inactivated quadrivalent influenza vaccine versus trivalent influenza vaccines in children aged 3-17 years. J Infect Dis 207:1878–1887

    CAS  PubMed Central  PubMed  Google Scholar 

  • Dormitzer PR, Tsai TF, Giuseppe Del Giudice G (2012) New technologies for influenza vaccines. Hum Vaccin Immunother 8:45–58

    CAS  PubMed  Google Scholar 

  • Dormitzer PR, Suphaphiphat P, Gibson DG, Wentworth DE, Stockwell TB, Algire MA, Alperovich N, Barro M, Brown DM, Craig S, Dattilo BM, Denisova EA, De Souza I, Eickmann M, Dugan VG, Ferrari A, Gomila RC, Han L, Judge C, Mane S, Matrosovich M, Merryman C, Palladino G, Palmer GA, Spencer T, Strecker T, Trusheim H, Uhlendorff J, Wen Y, Yee AC, Zaveri J, Zhou B, Becker S, Donabedian A, Mason PW, Glass JI, Rappuoli R, Venter JC (2013) Synthetic generation of influenza vaccine viruses for rapid response to pandemics. Sci Transl Med 5:185ra68

    Google Scholar 

  • Engelhardt OG (2013) Many ways to make an influenza virus–review of influenza virus reverse genetics methods. Influenza Other Respir Viruses 7:249–256

    CAS  PubMed  Google Scholar 

  • Esposito S, Tagliabue C, Tagliaferri L, Semino M, Longo MR, Principi N (2012) Preventing influenza in younger children. Clin Microbiol Infect 18(Suppl 5):42–49

    PubMed  Google Scholar 

  • European Medicines Agency (2008) Optaflu. http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000758/human_med_000952.jsp&mid=WC0b01ac058001d124. Accessed 23 Dec 2013

  • European Medicines Agency (2009) Celvaplan. http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000982/human_med_000690.jsp&mid=WC0b01ac058001d124. Accessed 23 Dec 2013

  • Fiore AE, Bridges CB, Cox NJ (2009) Seasonal influenza vaccines. Curr Top Microbiol Immunol 333:43–82

    CAS  PubMed  Google Scholar 

  • Food and Drug Administration (2012) Flucelvax. http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm328629.htm. Accessed 23 Dec 2013

  • Food and Drug Administration (2013) Flublok. http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm335836.htm. Accessed 23 Dec 2013

  • Fries LF, Smith GE, Glenn GM (2013) A recombinant virus-like particle influenza A (H7N9) vaccine. N Engl J Med 369:2564–2566

    CAS  PubMed  Google Scholar 

  • Galli G, Pittoni P, Tonti E, Malzone C, Uematsu Y, Tortoli M, Maione D, Volpini G, Finco O, Nuti S, Tavarini S, Dellabona P, Rappuoli R, Casorati G, Abrignani S (2007) Invariant NKT cells sustain specific B cell responses and memory. Proc Natl Acad Sci USA 104:3984–3989

    CAS  PubMed Central  PubMed  Google Scholar 

  • Galli G, Hancock K, Hoschler K, DeVos J, Praus M, Bardelli M, Malzone C, Castellino F, Gentile C, McNally T, Giuseppe Del Giudice G, Banzhoff A, Brauer V, Montomoli E, Zambon M, Katz J, Nicholson K, Stephenson I (2009a) Fast rise of broadly cross-reactive antibodies after boosting long-lived human memory B cells primed by an MF59 adjuvanted prepandemic vaccine. Proc Natl Acad Sci USA 106:7962–7967

    CAS  PubMed Central  PubMed  Google Scholar 

  • Galli G, Medini D, Borgogni E, Zedda L, Bardelli M, Malzone C, Nuti S, Tavarini S, Sammicheli C, Hilbert AK, Brauer V, Banzhoff A, Rappuoli R, Giuseppe Del Giudice G, Castellino F (2009b) Adjuvanted H5N1 vaccine induces early CD4+ T cell response that predicts long-term persistence of protective antibody levels. Proc Natl Acad Sci USA 106:3877–3882

    CAS  PubMed Central  PubMed  Google Scholar 

  • Garçon N, Vaughn DW, Didierlaurent AM (2012) Development and evaluation of AS03, an adjuvant system containing α-tocopherol and squalene in an oil-in-water emulsion. Expert Rev Vaccines 11:349–366

    PubMed  Google Scholar 

  • Gibson DG, Smith HO, Hutchison CA III, Venter JC, Merryman C (2010) Chemical synthesis of the mouse mitochondrial genome. Nat Methods 7:901–903

    CAS  PubMed  Google Scholar 

  • Goodwin K, Viboud C, Simonsen L (2006) Antibody response to influenza vaccination in the elderly: a quantitative review. Vaccine 24:1159–1169

    CAS  PubMed  Google Scholar 

  • Gorse GJ, Falsey AR, Johnson CM, Morrison D, Fried DL, Ervin JE, Greenberg DP, Ozol-Godfrey A, Landolfi V, Tsang PH (2013) Safety and immunogenicity of revaccination with reduced dose intradermal and standard dose intramuscular influenza vaccines in adults 18-64 years of age. Vaccine 31:6034–6040

    CAS  PubMed  Google Scholar 

  • Greenberg DP, Robertson CA, Noss MJ, Blatter MM, Biedenbender R, Decker MD (2013) Safety and immunogenicity of a quadrivalent inactivated influenza vaccine compared to licensed trivalent inactivated influenza vaccines in adults. Vaccine 31:770–776

    CAS  PubMed  Google Scholar 

  • Hafner AM, Corthésy B, Merkle HP (2013) Particulate formulations for the delivery of poly(I:C) as vaccine adjuvant. Adv Drug Deliv Rev 65:1386–1399

    CAS  PubMed  Google Scholar 

  • Halperin W, Weiss WI, Altman R, Diamond MA, Black KJ, Iaci AW, Black HC, Goldfield M (1979) A comparison of the intradermal and subcutaneous routes of influenza vaccination with A/New Jersey/76 (Swine flu) and A/Victoria/75: Report of a study and review of the literature. Am J Public Health 69:1247–1250

    CAS  PubMed Central  PubMed  Google Scholar 

  • Han F, Lin L, Warby SC, Faraco J, Li J, Dong SX, An P, Zhao L, Wang LH, Li QY, Yan H, Gao ZC, Yuan Y, Strohl KP, Mignot E (2011) Narcolepsy onset is seasonal and increased following the 2009 H1N1 pandemic in China. Ann Neurol 70:410–417

    PubMed  Google Scholar 

  • Hannoun C (2013) The evolving history of influenza viruses and influenza vaccines. Expert Rev Vaccines 12:1085–1094

    CAS  PubMed  Google Scholar 

  • Heier MS, Gautvik KM, Wannag E, Bronder KH, Midtlyng E, Kamaleri Y, Storsaeter J (2012) Incidence of narcolepsy in Norwegian children and adolescents after vaccination against H1N1 influenza A. Sleep Med 14:867–871

    Google Scholar 

  • Heikkinen T, Young J, van Beek E, Franke H, Verstraeten T, Weil JG, Della Cioppa G (2012) Safety of MF59-adjuvanted A/H1N1 influenza vaccine in pregnancy: a comparative cohort study. Am J Obstet Gynecol 207(3):177.e1-8

    Google Scholar 

  • Hekele A, Bertholet S, Archer J, Gibson DG, Palladino G, Brito LA, Otten GR, Brazzoli M, Buccato S, Bonci A, Casini D, Maione D, Qi ZQ, Gill JE, Caiazza NC, Urano J, Hubby B, Gao GF, Shu Y, De Gregorio E, Mandl CW, Mason PW, Settembre EC, Ulmer JB, Venter JC, Dormitzer PR, Rappuoli R, Geall AJ (2013) Rapidly produced SAM® vaccine against H7N9 influenza is immunogenic in mice. Emerg Microb Infect 2:e52

    Google Scholar 

  • Hennessy AV, Davenport FM (1961) Relative merits of aqueous and adjuvant influenza vaccines when used in a two-dose schedule. Public Health Rep 76:411–419

    CAS  PubMed Central  PubMed  Google Scholar 

  • Hobson D, Curry RL, Beare AS, Ward-Gardner A (1972) The role of serum haemagglutination-inhibiting antibody in protection against challenge infection with influenza A2 and B virus. J Hyg (Lond) 70:767–777

    CAS  Google Scholar 

  • Iob A, Brianti G, Zamparo E, Gallo T (2005) Evidence of increased clinical protection of an MF59-adjuvant influenza vaccine compared to a non-adjuvant vaccine among elderly residents of long-term care facilities in Italy. Epidemiol Infect 133:687–693

    CAS  PubMed Central  PubMed  Google Scholar 

  • Jain V, Rivera L, Zaman K, Espos RA Jr, Sirivichayakul C, Quiambao BP, Rivera-Medina DM, Kerdpanich P, Ceyhan M, Dinleyici EC, Cravioto A, Yunus M, Chanthavanich P, Linkittikul K, Kurugol Z, Alhan E, Caplanusi A, Durviaux S, Boutet P, Ofori-Anyinam O, Chandrasekaran V, Dbaibo G, Innis BL (2013) Vaccine for prevention of mild and moderate-to-severe influenza in children N Engl J Med Epub. doi:10.1056/NEJMoa1215817

    Google Scholar 

  • Jefferson T, Rivetti A, Di Pietrantonj C, Demicheli V, Ferroni E (2012) Vaccines for preventing influenza in healthy children. Cochrane Database Syst Rev 8:CD004879

    Google Scholar 

  • Karlsson EA, Marcelin G, Webby RJ, Schultz-Cherry S (2012) Review on the impact of pregnancy and obesity on influenza virus infection. Influenza Other Respir Viruses 6:449–460

    PubMed  Google Scholar 

  • Katz JM, Webster RG (1989) Efficacy of inactivated influenza A virus (H3N2) vacvcines grown in mammalian cells or embryonated eggs. J Infect Dis 160:191–198

    CAS  PubMed  Google Scholar 

  • Kendal AP, Bozeman FM, Ennis FA (1980) Further studies of the neuraminidase content of inactivated influenza vaccines and the neuraminidase antibody responses after vaccination of immunologically primed and unprimed populations. Infect Immun 29:966–971

    CAS  PubMed Central  PubMed  Google Scholar 

  • Kenney RT, Frech SA, Muenz LR, Villar CP, Glenn GM (2004) Dose sparing with intradermal injection of influenza vaccine. N Engl J Med 351:2295–2301

    CAS  PubMed  Google Scholar 

  • Khurana S, Suguitan A Jr, Rivera Y, Simmons CP, Lanzavecchia A, Sallusto F, Manischewitz J, King LR, Subbarao K, Golding H (2009) Antigenic fingerprinting of H5N1 avian influenza using convalescent sera and monoclonal antibodies reveals potential vaccine and diagnostic tools. PLoS Med 6:e1000049. doi: 10.1371/journal.pmed.1000049

  • Khurana S, Chearwae W, Castellino F, Manischewitz J, King LR, Honorkiewicz A, Rock MT, Edwards KM, Giuseppe Del Giudice G, Rappuoli R, Golding H (2010) MF59-adjuvanted vaccines expand antibody repertoires targeting protective sites of pandemic H5N1 influenza virus. Sci Transl Med 2:15ra5

    Google Scholar 

  • Khurana S, Verma N, Yewdell JW, Hilbert AK, Castellino F, Lattanzi M, Giuseppe Del Giudice G, Rappuoli R, Golding H (2011) MF59 adjuvant enhances diversity and affinity of antibody-mediated immune response to pandemic influenza viruses. Sci Transl Med 3:85ra48

    Google Scholar 

  • Khurana S, Wu J, Verma N, Verma S, Raghunandan R, Manischewitz J, King LR, Kpamegan E, Pincus S, Smith G, Glenn G, Golding H (2011b) H5N1 virus-like particle vaccine elicits cross-reactive neutralizing antibodies that preferentially bind to the oligomeric form of influenza virus hemagglutinin in humans. J Virol 85:10945–10954

    CAS  PubMed Central  PubMed  Google Scholar 

  • Khurana S, Loving CL, Manischewitz J, King LR, Gauger PC, Henningson J, Vincent AL, Golding H (2013) Vaccine-induced anti-HA2 antibodies promote virus fusion and enhance influenza virus respiratory disease. Sci Transl Med 5:200ra114

    Google Scholar 

  • Kieninger D, Sheldon E, Lin WY, Yu CJ, Bayas JM, Gabor JJ, Esen M, Fernandez Roure JL, Narejos Perez S, Alvarez Sanchez C, Feng Y, Claeys C, Peeters M, Innis BL, Jain V (2013) Immunogenicity, reactogenicity and safety of an an inactivated quadrivalent influenza vaccine candidate versus inactivated trivalent influenza vaccine: a phase III, randomized trial in adults aged >18 years. BMC Infect Dis 13(1):343

    Google Scholar 

  • Klucker MF, Dalençon F, Probeck P, Haensler J (2012) AF03, an alternative squalene emulsion-based vaccine adjuvant prepared by phase inversion temperature method. J Pharm Sci 101:4490–4500

    PubMed  Google Scholar 

  • Langley JM, Carmona Martinez A, Chatterjee A, Halperin SA, McNeil S, Reisinger KS, Aggarwal N, Haung LM, Peng CT, Garcia-Sicilia J, Salamanca de la Cueva I, Cabañas F, Treviño-Garza C, Rodriguez-Weber MA, de la OM, Chandrasekaran V, Dewé W, Liu A, Innis BL, Jain V (2013) Immunogenicity and safety of an inactivated quadrivalent influenza vaccine candidate: a phase III randomized controlled trial in children. J Infect Dis 208:544–553

    CAS  PubMed Central  PubMed  Google Scholar 

  • Legrand J, Vergu E, Flahault A (2006) Real-time monitoring of the influenza vaccine field effectiveness. Vaccine 24:6605–6611

    PubMed  Google Scholar 

  • Leroux-Roels I, Leroux-Roels G (2009) Current status and progress of prepandemic and pandemic influenza vaccine development. Expert Rev Vaccines 8:401–423

    CAS  PubMed  Google Scholar 

  • Leroux-Roels I, Vets E, Freese R, Seiberling M, Weber F, Salamand C, Leroux-Roels G (2008) Seasonal influenza vaccine delivered by intradermal microinjection: a randomized controlled safety and immunogenicity trial in adults. Vaccine 26:6614–6619

    CAS  PubMed  Google Scholar 

  • Levie K, Leroux-Roels I, Hoppenbrouwers K, Kervyn AD, Vandermeulen C, Forgus S, Leroux-Roels G, Pichon S, Kusters I (2008) An adjuvanted, low-dose, pandemic influenza A (H5N1) vaccine candidate is safe, immunogenic, and induces cross-reactive immune responses in healthy adults. J Infect Dis 198:642–649

    PubMed  Google Scholar 

  • Livingston BD, Higgins D, Van Nest G (2006) Evolving strategies for the prevention of influenza infection: potential for multistrain targeting. BioDrugs 6:335–340

    Google Scholar 

  • López-Macías C, Ferat-Osorio E, Tenorio-Calvo A, Isibasi A, Talavera J, Arteaga-Ruiz O, Arriaga-Pizano L, Hickman SP, Allende M, Lenhard K, Pincus S, Connolly K, Raghunandan R, Smith G, Glenn G (2011) Safety and immunogenicity of a virus-like particle pandemic influenza A (H1N1) 2009 vaccine in a blinded, randomized, placebo-controlled trial of adults in Mexico. Vaccine 29:7826–7834

    PubMed  Google Scholar 

  • Ludvigsson JF, Zugna D, Cnattingius S, Richiardi L, Ekbom A, Örtqvist Å, Persson I, Stephansson O (2013) Influenza H1N1 vaccination and adverse pregnancy outcome. Eur J Epidemiol 28:579–588

    CAS  PubMed  Google Scholar 

  • Mannino S, Villa M, Apolone G, Weiss NS, Groth N, Aquino I, Boldori L, Caramaschi F, Gattinoni A, Malchiodi G, Rothman KJ (2012) Effectiveness of adjuvanted influenza vaccination in elderly subjects in northern Italy. Am J Epidemiol 176:527–533

    PubMed Central  PubMed  Google Scholar 

  • Marcelin G, Sandbulte MR, Webby RJ (2012) Contribution of antibody production against neuraminidase to the protection afforded by influenza vaccines. Rev Med Virol 22:267–279

    CAS  PubMed Central  PubMed  Google Scholar 

  • McElhaney JE, Xie D, Hager WD, Barry MB, Wang Y, Kleppinger A, Ewen C, Kane KP, Bleackley RC (2006) T cell responses are better correlates of vaccine protection in the elderly. J Immunol 176:6333–6339

    CAS  PubMed  Google Scholar 

  • McElhaney JE, Beran J, Devaster JM, Esen M, Launay O, Leroux-Roels G, Ruiz-Palacios GM, van Essen GA, Caplanusi A, Claeys C, Durand C, Duval X, El Idrissi M, Falsey AR, Feldman G, Frey SE, Galtier F, Hwang SJ, Innis BL, Kovac M, Kremsner P, McNeil S, Nowakowski A, Richardus JH, Trofa A, Oostvogels L, Influence65 study group (2013) AS03-adjuvanted versus non-adjuvanted inactivated trivalent influenza vaccine against seasonal influenza in elderly people: a phase 3 randomised trial. Lancet Infect Dis 13:485–496

    CAS  PubMed  Google Scholar 

  • McKeage K (2013) Inactivated quadrivalent split-virus seasonal influenza vaccine (Fluarix® quadrivalent): a review of its use in the prevention of disease caused by influenza A and B. Drugs 73:1587–1594

    CAS  PubMed  Google Scholar 

  • Meier S, Bel M, L’huillier A, Crisinel PA, Combescure C, Kaiser L, Grillet S, Pósfay-Barbe K, Siegrist CA; H1N1 Epidemiology Study Group of Geneva (2011) Antibody responses to natural influenza A/H1N1/09 disease or following immunization with adjuvanted vaccines, in immunocompetent and immunocompromised children. Vaccine 29:3548–3557

    Google Scholar 

  • Melén K, Partinen M, Tynell J, Sillanpää M, Himanen SL, Saarenpää-Heikkilä O, Hublin C, Olsen P, Ilonen J, Nohynek H, Syrjänen R, Kilpi T, Vuorela A, Kirjavainen T, Vaarala O, Julkunen I (2013) No serological evidence of influenza A H1N1pdm09 virus infection as a contributing factor in childhood narcolepsy after Pandemrix vaccination campaign in Finland. PLoS ONE 8:e68402

    PubMed Central  PubMed  Google Scholar 

  • Mertz D, Kim TH, Johnstone J, Lam PP, Science M, Kuster SP, Fadel SA, Tran D, Fernandez E, Bhatnagar N, Loeb M (2013) Populations at risk for severe or complicated influenza illness: systematic review and meta-analysis. BMJ 347:f5061. doi:10.1136/bmj.f5061

    PubMed Central  PubMed  Google Scholar 

  • Miller E, Andrews N, Stellitano L, Stowe J, Winstone AM, Shneerson J, Verity C (2013) Risk of narcolepsy in children and young people receiving AS03 adjuvanted pandemic A/H1N1 2009 influenza vaccine: retrospective analysis. BMJ 346:f794

    PubMed  Google Scholar 

  • Monto AS, Kendal AP (1973) Effect of neuraminidase antibody on Hong Kong influenza. Lancet 1:623–625

    CAS  PubMed  Google Scholar 

  • Montomoli E, Capecchi B, Hoschler K (2011) Correlates of protection against influenza. In: Rappuoli R, Giuseppe Del Giudice G (eds) Influenza vaccines for the future, 2nd edn. Springer, Basel, pp 199–222

    Google Scholar 

  • Morel S, Didierlaurent A, Bourguignon P, Delhaye S, Baras B, Jacob V, Planty C, Elouahabi A, Harvengt P, Carlsen H, Kielland A, Chomez P, Garçon N, Van Mechelen M (2011) Adjuvant system AS03 containing α-tocopherol modulates innate immune response and leads to improved adaptive immunity. Vaccine 29:2461–2473

    CAS  PubMed  Google Scholar 

  • Moris P, van der Most R, Leroux-Roels I, Clement F, Dramé M, Hanon E, Leroux-Roels G, Van Mechelen M (2011) H5N1 influenza vaccine formulated with AS03a induces strong cross-reactive and polyfunctional CD4 T-cell responses. J Clin Immunol 31:443–454

    CAS  PubMed Central  PubMed  Google Scholar 

  • Moro PL, Harrington T, Shimabukuro T, Cano M, Museru OI, Menschik D, Broder K (2013) Adverse events after Fluzone® intradermal vaccine reported to the Vaccine Adverse Event Reporting System (VAERS), 2011-2013. Vaccine 31:4984–4987

    PubMed  Google Scholar 

  • Mosca F, Tritto E, Muzzi A, Monaci E, Bagnoli F, Iavarone C, O’Hagan D, Rappuoli R, De Gregorio E (2008) Molecular and cellular signatures of human vaccine adjuvants. Proc Natl Acad Sci USA 105:10501–10506

    CAS  PubMed Central  PubMed  Google Scholar 

  • Moser C, Amacker M, Zurbriggen R (2011) Influenza virosomes as a vaccine adjuvant and carrier system. Expert Rev Vaccines 10:437–446

    CAS  PubMed  Google Scholar 

  • Mostow SR, Schoenbaum SC, Dowdle WR, Coleman MT, Kaye HS, Hierholzer JC (1970) Studies on inactivated influenza vaccines. II. Effect of increasing dosage on antibody response and adverse reactions in man. Am J Epidemiol 92:248–256

    CAS  PubMed  Google Scholar 

  • National Narcolepsy Study Steeting Committee Ireland (2012) Investigation of an increase in the incidence of narcolepsy in children and adolescents in 2009 and 2010. http://healthupdate.gov.ie/wp-content/uploads/2012/04/Final_Report_of_National_Narcolepsy_Study_Steering_Committee-latest1.pdf. Accessed 27 Dec 2013

  • Nohynek H, Jokinen J, Partinen M, Vaarala O, Kirjavainen T, Sundman J, Himanen SL, Hublin C, Julkunen I, Olsén P, Saarenpää-Heikkilä O, Kilpi T (2012) AS03 adjuvanted AH1N1 vaccine associated with an abrupt increase in the incidence of childhood narcolepsy in Finland. PLoS ONE 7:e33536

    CAS  PubMed Central  PubMed  Google Scholar 

  • O’Hagan DT, Ott GS, Nest GV, Rappuoli R, Giuseppe Del Giudice G (2013) The history of MF59® adjuvant: a phoenix that arose from the ashes. Expert Rev Vaccines 12:13–30

    PubMed  Google Scholar 

  • Osterholm MT, Kelley NS, Sommer A, Belongia EA (2012) Efficacy and effectiveness of influenza vaccines: a systematic review and meta-analysis. Lancet Infect Dis 12:36–44

    PubMed  Google Scholar 

  • Oxford J, Gilbert A, Lambkin-Williams R (2011) Influenza vaccines have a short but illustrious history of dedicated science enabling the rapid global production of A/swine (H1N1) vaccine in the current pandemic. In: Rappuoli R, Giuseppe Del Giudice G (eds) Influenza vaccines for the future, 2nd edition, Springer, Basel, pp 115–147

    Google Scholar 

  • Partinen M, Saarenpää-Heikkilä O, Ilveskoski I, Hublin C, Linna M, Olsén P, Nokelainen P, Alén R, Wallden T, Espo M, Rusanen H, Olme J, Sätilä H, Arikka H, Kaipainen P, Julkunen I, Kirjavainen T (2012) Increased incidence and clinical picture of childhood narcolepsy following the 2009 H1N1 pandemic vaccination campaign in Finland. PLoS ONE 7:e33723

    CAS  PubMed Central  PubMed  Google Scholar 

  • Pedersen GK, Madhun AS, Breakwell L, Hoschler K, Sjursen H, Pathirana RD, Goudsmit J, Cox RJ (2012) T-helper 1 cells elicited by H5N1 vaccination predict seroprotectioN. J Infect Dis 206:158–166

    CAS  PubMed  Google Scholar 

  • Pellegrini M, Nicolay U, Lindert K, Groth N, Della Cioppa G (2009) MF59-adjuvanted versus non-adjuvanted influenza vaccines: integrated analysis from a large safety database. Vaccine 27:6959–6965

    CAS  PubMed  Google Scholar 

  • Pépin S, Donazzolo Y, Jambrecina A, Salamand C, Saville M (2013) Safety and immunogenicity of a quadrivalent inactivated influenza vaccine in adults. Vaccine 31:5572–5578

    PubMed  Google Scholar 

  • Pica N, Palese P (2013) Toward a universal influenza virus vaccine: prospects and challenges. Annu Rev Med 64:189–202

    CAS  PubMed  Google Scholar 

  • Podda A (2001) The adjuvanted influenza vaccines with novel adjuvants: Experience with the MF59-adjuvanted vaccine. Vaccine 19:2673–2680

    CAS  PubMed  Google Scholar 

  • Poland G, Morse D (2010) Improving the public health: the US recommendation for universal influenza immunization. Vaccine 28:2799–2800

    PubMed  Google Scholar 

  • Powell TJ, Peng Y, Berthoud TK, Blais ME, Lillie PJ, Hill AV, Rowland-Jones SL, McMichael AJ, Gilbert SC, Dong T (2013) Examination of influenza specific T cell responses after influenza virus challenge in individuals vaccinated with MVA-NP + M1 vaccine. PLoS ONE 8:e62778

    CAS  PubMed Central  PubMed  Google Scholar 

  • Puig-Barberà J, Diez-Domingo J, Pérez Hoyos S, Belenguer Varea A, González Vidal D (2004) Effectiveness of the MF59-adjuvanted influenza vaccine in preventing emergency admissions for pneumonia in the elderly over 64 years of age. Vaccine 23:283–289

    PubMed  Google Scholar 

  • Puig-Barberà J, Díez-Domingo J, Varea AB, Chavarri GS, Rodrigo JA, Hoyos SP, Vidal DG (2007) Effectiveness of MF59-adjuvanted subunit influenza vaccine in preventing hospitalisations for cardiovascular disease, cerebrovascular disease and pneumonia in the elderly. Vaccine 25:7313–7321

    PubMed  Google Scholar 

  • Pushko P, Pearce MB, Ahmad A, Tretyakova I, Smith G, Belser JA, Tumpey TM (2011) Influenza virus-like particle can accommodate multiple subtypes of hemagglutinin and protect from multiple influenza types and subtypes. Vaccine 29:5911–5918

    CAS  PubMed  Google Scholar 

  • Rahier JF, Papay P, Salleron J, Sebastian S, Marzo M, Peyrin-Biroulet L, Garcia-Sanchez V, Fries W, van Asseldonk DP, Farkas K, de Boer NK, Sipponen T, Ellul P, Louis E, Peake ST, Kopylov U, Maul J, Makhoul B, Fiorino G, Yazdanpanah Y, Chaparro M, European Crohn’s Colitis Organisation (ECCO) (2011) H1N1 vaccines in a large observational cohort of patients with inflammatory bowel disease treated with immunomodulators and biological therapy. Gut 60:456–462

    PubMed  Google Scholar 

  • Reed C, Metzer MI, Finelli L, Fiore A (2012) Public health impact of including two lineages of influenza B in a quadrivalent seasonal influenza vaccine. Vaccine 30:1993–1998

    PubMed  Google Scholar 

  • Renfrey S (1994) Watts A (1994) Morphological and biochemical characterization of influenza vaccines commercially available in the United Kingdom. Vaccine 12:747–752

    CAS  PubMed  Google Scholar 

  • Riedl K, Riedl R, von Gabain A, Nagy E, Lingnau K (2008) The novel adjuvant IC31 strongly improves influenza vaccine-specific cellular and humoral immune responses in young adult and aged mice. Vaccine 26:3461–3468

    CAS  PubMed  Google Scholar 

  • Rimmelzwaan GF, Nieuwkoop N, Brandenburg A, Sutter G, Beyer WE, Maher D, Bates J, Osterhaus AD (2000) A randomized, double blind study in young healthy adults comparing cell mediated and humoral immune responses induced by influenza ISCOM vaccines and conventional vaccines. Vaccine 19:1180–1187

    CAS  PubMed  Google Scholar 

  • Rubinstein F, Micone P, Bonotti A, Wainer V, Schwarcz A, Augustovski F, Pichon Riviere A, Karolinski A; EVA Study Research Group Estudio Embarazo y Vacuna Antigripal (2013) Influenza A/H1N1 MF59 adjuvanted vaccine in pregnant women and adverse perinatal outcomes: multicentre study. BMJ 346:f393

    Google Scholar 

  • Rümke HC, Richardus JH, Rombo L, Pauksens K, Plassmann G, Durand C, Devaster JM, Dewé W, Oostvogels L (2013) Selection of an adjuvant for seasonal influenza vaccine in elderly people: modelling immunogenicity from a randomized trial. BMC Infect Dis 13:348

    PubMed Central  PubMed  Google Scholar 

  • Salk JE (1953) Use of adjuvants in studies on influenza immunization. III. Degree of persistence of antibody in subjects two years after vaccination. JAMA 151:1169–1175

    CAS  Google Scholar 

  • Salk JE, Bailey ML, Laurel AM (1952) The use of adjuvants in studies on influenza immunization. II. Increased antibody formation in human subjects inoculated with influenza virus vaccine in a water-in-oil emulsion. Am J Hyg 55:439–456

    CAS  PubMed  Google Scholar 

  • Scheifele DW, McNeil SA, Ward BJ, Dionne M, Cooper C, Coleman B, Loeb M, Rubinstein E, McElhaney J, Hatchette T, Li Y, Montomoli E, Schneeberg A, Bettinger JA, Halperin SA, Research Network CI (2013) Safety, immunogenicity, and tolerability of three influenza vaccines in older adults: Results of a randomized, controlled comparison. Hum Vaccin Immunother 9:2460–2473

    PubMed Central  PubMed  Google Scholar 

  • Schild GC, Wood JM, Newman RW (1975) A single-radial-immunodiffusion technique for the assay of influenza haemagglutinin antigen. Proposals for an assay method for the haemagglutinin content of influenza vaccines. Bull World Health Organ 52:223–231

    CAS  PubMed Central  PubMed  Google Scholar 

  • Schultze V, D’Agosto V, Wack A, Novicki D, Zorn J, Hennig R (2008) Safety of MF59 adjuvant. Vaccine 26:3209–3222

    CAS  PubMed  Google Scholar 

  • Spensieri F, Borgogni E, Zedda L, Bardelli M, Buricchi F, Volpini G, Fragapane E, Tavarini S, Finco O, Rappuoli R, Giuseppe Del Giudice G, Galli G, Castellino F (2013) Human circulating influenza-CD4+ ICOS1+IL-21 + T cells expand after vaccination, exert helper function, and predict antibody responses. Proc Natl Acad Sci USA 110:14330–14335

    CAS  PubMed Central  PubMed  Google Scholar 

  • Sridhar S, Begom S, Bermingham A, Hoschler K, Adamson W, Carman W, Bean T, Barclay W, Deeks JJ, Lalvani A (2013) Cellular immune correlates of protection against symptomatic pandemic influenza. Nat Med 19:1305–1312

    CAS  PubMed  Google Scholar 

  • Stephenson I, Nicholson KG, Hoschler K, Zambon MC, Hancock K, DeVos J, Katz JM, Praus M, Banzhoff A (2008) Antigenically distinct MF59-adjuvanted vaccine to boost immunity to H5N1. N Engl J Med 359:1631–1633

    CAS  PubMed  Google Scholar 

  • Sullivan SJ, Jacobson R, Poland GA (2010) Advances in the vaccination of the elderly against influenza: role of a high-dose vaccine. Expert Rev Vaccines 9:1127–1133

    CAS  PubMed  Google Scholar 

  • Szakács A, Darin N, Hallböök T (2013) Increased childhood incidence of narcolepsy in western Sweden after H1N1 influenza vaccination. Neurology 80:1315–1321

    PubMed  Google Scholar 

  • Taylor DN, Treanor JJ, Sheldon EA, Johnson C, Umlauf S, Song L, Kavita U, Liu G, Tussey L, Ozer K, Hofstaetter T, Shaw A (2012) Development of VAX128, a recombinant hemagglutinin (HA) influenza-flagellin fusion vaccine with improved safety and immune response. Vaccine 30:5761–5769

    CAS  PubMed  Google Scholar 

  • Thompson WW, Shay DK, Weintraub E, Brammer L, Cox N, Anderson LJ, Fukuda K (2003) Mortality associated with influenza and RSV. JAMA 289:179–186

    PubMed  Google Scholar 

  • Thompson WW, Shay DK, Weintraub E, Brammer L, Bridges CB, Cox NJ, Fukuda K (2004) Influenza-associated hospitalizations in the United States. JAMA 292:1333–1340

    CAS  PubMed  Google Scholar 

  • Thompson MG, Shay DK, Zhou H, Bridges CB, Cheng PY, Burns E, Bresee JS, Cox NJ (2010) Estimates of deaths associated with seasonal influenza – United States 1976-2007. MMWR 59:1057–1062

    Google Scholar 

  • Treanor JJ, Essink B, Hull S, Reed S, Izikson R, Patriarca P, Goldenthal KL, Kohberger R, Dunkle LM (2013) Evaluation of safety and immunogenicity of recombinant influenza hemagglutinin (H5/Indonesia/05/2005) formulated with and without a stable oil-inwater emulsion containing glucopyranosyl-lipid A (SE+GLA) adjuvant. Vaccine 31(48):5760–5765

    Google Scholar 

  • Tsai T, Giuseppe Del Giudice G, Crucitti A, Weil J, Narasimhan V (2013) Is the adjuvant solely to blame? BMJ 346:f2375. doi:10.1136/bmj.f2375

    PubMed  Google Scholar 

  • Tsang P, Gorse GJ, Strout CB, Sperling M, Greenberg DP, Ozol-Godfrey A, Diazgranados C, Landolfi V (2013) Immunogenicity and safety of Fluzone® intradermal and high-dose influenza vaccines in older adults ≥ 65 years of age: A randomized, controlled, phase II trial. Vaccine Epub. doi:10.1016/j.vaccine.2013.09.074

    Google Scholar 

  • Turley CB, Rupp RE, Johnson C, Taylor DN, Wolfson J, Tussey L, Kavita U, Stanberry L, Shaw A (2011) Safety and immunogenicity of a recombinant M2e-flagellin influenza vaccine (STF2.4xM2e) in healthy adults. Vaccine 29:5145–5152

    CAS  PubMed  Google Scholar 

  • Van Buynder PG, Konrad S, Van Buynder JL, Brodkin E, Krajden M, Ramler G, Bigham M (2013) The comparative effectiveness of adjuvanted and unadjuvanted trivalent inactivated influenza vaccine (TIV) in the elderly. Vaccine 31:6122–6128

    PubMed  Google Scholar 

  • van der Velden MV, Fritz R, Pöllabauer EM, Portsmouth D, Howard MK, Kreil TR, Dvorak T, Fritsch S, Vesikari T, Diez-Domingo J, Richmond P, Lee BW, Kistner O, Ehrlich HJ, Barrett PN, Aichinger G (2014) Safety and Immunogenicity of a Vero Cell Culture-Derived Whole-Virus Influenza A(H5N1) Vaccine in a Pediatric Population. J Infect Dis 209:12–23

    PubMed  Google Scholar 

  • Vesikari T, Pellegrini M, Karvonen A, Groth N, Borkowski A, O’Hagan DT, Podda A (2009a) Enhanced immunogenicity of seasonal influenza vaccines in young children using MF59 adjuvant. Pediatr Infect Dis J 28:563–571

    PubMed  Google Scholar 

  • Vesikari T, Groth N, Karvonen A, Borkowski A, Pellegrini M (2009b) MF59-adjuvanted influenza vaccine (Fluad®) in children: safety and immunogenicity following a second year seasonal vaccination. Vaccine 27:6291–6295

    CAS  PubMed  Google Scholar 

  • Vesikari T, Knuf M, Wutzler P, Karvonen A, Kieninger-Baum D, Schmitt HJ, Baehner F, Borkowski A, Tsai TF, Clemens R (2011) Oil-in-water emulsion adjuvant with influenza vaccine in young children. N Engl J Med 365:1406–1416

    CAS  PubMed  Google Scholar 

  • Vesikari T, Forstén A, Borkowski A, Gaitatzis N, Banzhoff A, Clemens R (2012a) Homologous and heterologous antibody responses to a one-year booster dose of an MF59® adjuvanted A/H5N1 pre-pandemic influenza vaccine in pediatric subjects. Hum Vaccin Immunother 8:921–928

    CAS  PubMed  Google Scholar 

  • Vesikari T, Pepin S, Kusters I, Hoffenbach A, Denis M (2012b) Assessment of squalene adjuvanted and non-adjuvanted vaccines against pandemic H1N1 influenza in children 6 months to 17 years of age. Hum Vaccin Immunother 8:1283–1292

    CAS  PubMed Central  PubMed  Google Scholar 

  • Villa M, Black S, Groth N, Rothman KJ, Apolone G, Weiss NS, Aquino I, Boldori L, Caramaschi F, Gattinoni A, Malchiodi G, Crucitti A, Della Cioppa G, Scarpini E, Mavilio D, Mannino S (2013) Safety of MF59-adjuvanted influenza vaccination in the elderly: results of a comparative study of MF59-adjuvanted vaccine versus nonadjuvanted influenza vaccine in northern Italy. Am J Epidemiol 178:1139–1145

    PubMed Central  PubMed  Google Scholar 

  • Vono M, Taccone M, Caccin P, Gallotta M, Donvito G, Falzoni S, Palmieri E, Pallaoro M, Rappuoli R, Di Virgilio F, De Gregorio E, Montecucco C, Seubert A (2013) The adjuvant MF59 induces ATP release from muscle that potentiates response to vaccination. Proc Natl Acad Sci USA 110:21095–21100

    CAS  PubMed Central  PubMed  Google Scholar 

  • Wilkinson TM, Li CK, Chui CS, Huang AK, Perkins M, Liebner JC, Lambkin-Williams R, Gilbert A, Oxford J, Nicholas B, Staples KJ, Dong T, Douek DC, McMichael AJ, Xu XN (2012) Preexisting influenza-specific CD4+ T cells correlate with disease protection against influenza challenge in humans. Nat Med 18:274–280

    CAS  PubMed  Google Scholar 

  • Wilschut J (2009) Influenza vaccines: the virosome concept. Immunol Lett 122:118–121

    CAS  PubMed  Google Scholar 

  • World Health Organization (2012) Meeting of the Strategic Advisory Group of Experts on immunization, April 2012 – conclusions and recommendations. Weekly Epidemiol Rec 87:201–216

    Google Scholar 

  • World Health Organization (2013) http://www.who.int/influenza/vaccines/virus/recommendations/201309_recommendation.pdf. Accessed 23 Dec 2013

  • Zaman A, Holmes TH, Stamatis S, Tu WW, He XS, Bouvier N, Kemble G, Greenberg HB, Lewis DB, Arvin AM, Dekker CL (2007) Humoral and cellular immune responses in children given annual immunization with trivalent inactivated influenza vaccine. Pediatr Infect Dis J 26:107–115

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Research and Development, Novartis Vaccines, Via Fiorentina 1, 53100, Siena, Italy

    Giuseppe Del Giudice & Rino Rappuoli

Authors
  1. Giuseppe Del Giudice
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Rino Rappuoli
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Rino Rappuoli .

Editor information

Editors and Affiliations

  1. Department of Immunology and Microbial Science, The Scripps Research Institute, La Jolla, California, USA

    Michael B. A. Oldstone

  2. IDepartment of Microbiology and Immunology, Emory University, Atlanta, Georgia, USA

    Richard W. Compans

Rights and permissions

Reprints and permissions

Copyright information

© 2014 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Del Giudice, G., Rappuoli, R. (2014). Inactivated and Adjuvanted Influenza Vaccines. In: Oldstone, M., Compans, R. (eds) Influenza Pathogenesis and Control - Volume II. Current Topics in Microbiology and Immunology, vol 386. Springer, Cham. https://doi.org/10.1007/82_2014_406

Download citation

Publish with us

Policies and ethics

Search

Navigation